Re: the Targacept (a company which I like a lot) deal with GSK.
This is not OT, there was an interesting aside during the conference call which is relevant to Cortex. The GSK licensing exec on the call was asked about GSK's previous work with NNR's, and he stated that GSK would not have inlicensed a program that would "compete" with an inhouse program (tapping the same target). In other words, if they'd had a full-fledged NNR program inhouse, they would not have licensed Targacept's. It reminds me of the discussions we have had in the past about potential partners, Lilly in particular due to their history with Ampa-modulators. This may be a hint as to why Lilly has been resistant to partnering--not wanting to acquire something that 'competes' with inhouse work, due to (I presume) the toll that could take on internal morale--if not exactly espousing a rejection of what is 'not invented here', certainly emphasizing prioritization of programs that are 'invented here.'
To the degree to which this may also be a factor at some other Big Pharma companies, this gives a hint that we might need to look at those without much invested in internal Ampa-type programs (or even other glutamate-based, like mGluR)--where there are fewer inhouse 'feathers' to be ruffled.
NeuroInvestment
Market Data 
Markets 
AI
